Testing maintenance olaparib versus observation after chemoradiation for p53 abnormal endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether taking a daily pill called olaparib after standard chemoradiation can help prevent endometrial cancer with a p53 mutation from coming back. Half of participants will receive olaparib, and the other half will just be watched closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage I, II, or III endometrial cancer that has grown into the muscle layer, and the cancer type is one of the common subtypes (like endometrioid, serous, or clear cell).
- Your tumor must have a specific genetic makeup: abnormal p53, normal mismatch repair, and non-pathogenic POLE (your doctor will check this).
- You have completed or are scheduled to receive a specific combination of chemotherapy and radiation, usually starting within 6–10 weeks after surgery.
- You are generally healthy enough for daily activities (ECOG 0 or 1), weigh more than 66 pounds, and have good kidney, liver, and bone marrow function.
- You have not had pelvic radiation before, and you have no other active cancer (except for certain early-stage or treated skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies which after-surgery (adjuvant) treatment works best when endometrial cancer is classified by specific tumor DNA/molecular features. You may be offered treatment based on the tumor results, aiming to improve outcomes and lower the risk of the cancer coming back.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This study is testing whether a special kind of medicine called a PARP inhibitor can work against endometrial cancer cells grown in a lab from your tumor. The goal is to find out which patients might benefit from this treatment in the future.
This study looks at how well two drugs, durvalumab and olaparib, work together after initial chemotherapy for advanced or recurrent endometrial cancer. It may help patients who have not had many treatment options before.
This trial compares chemotherapy alone with chemotherapy plus radiation after surgery for endometrial cancer. It is specifically for tumors that have a p53 mutation, to see which treatment helps prevent the cancer from coming back or progressing.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.